Please login to the form below
eczema
This page shows the latest eczema news and features for those working in and with pharma, biotech and healthcare.
Almirall receives CHMP recommendation for lebrikizumab in atopic dermatitis
Typically referred to as eczema, atopic dermatitis is a chronic, inflammatory disease of the skin characterised by recurrent inflammation associated with intense pruritus or itching.
Latest news
-
World Atopic Eczema Day 2023: Almirall unveils awareness campaign
In observance of this year’s World Atopic Eczema Day on 14 September, Almirall has unveiled its atopic dermatitis awareness campaign, entitled ‘Moving aheAD’. ... Atopic dermatitis, or atopic eczema, is a chronic, inflammatory disease of the skin
-
Incyte shares positive results for Opzelura cream in children with atopic dermatitis
type of eczema.
-
Sanofi’s amlitelimab shows promise in phase 2b atopic dermatitis trial
Typically referred to as eczema, atopic dermatitis affects an estimated 16.5 million adults in the US, with nearly 40% affected by moderate-to-severe cases.
-
Dermavant’s Vtama cream shows promise in phase 3 atopic dermatitis trial
More commonly referred to as eczema, atopic dermatitis is one of the most common inflammatory skin diseases, affecting over 26 million people in the US alone and up to 30% of
-
Almirall and Eli Lilly’s lebrikizumab shows continued improvement in atopic dermatitis
Typically referred to as eczema, atopic dermatitis is one of the most common inflammatory skin diseases, affecting up to 4.4% of adults in the EU.
More from news
Approximately 15 fully matching, plus 69 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
Dupixent for eczema and asthma – in order to ramp up internal generation of new drug candidates.
-
Drug launches to watch in 2019
Meanwhile, phase 2b results for upadacitinib showed that the drug was able to improve skin lesions and itching in patients with moderate-to- severe atopic dermatitis (eczema) across all doses tested,
-
Case Study: Skin-telligence
One in two eczema sufferers aren’t happy with their treatment regime and actively switch products, trying different treatments to find the right one. ... Eczema has a psychological impact. Half of respondents said their skin affects their confidence.
-
Embracing digital disruption in pharma
HelloSkin is the number one online store for emollients, nutrition supplements, accessories and selected over-the-counter products for people living with psoriasis, eczema, acne and dry skin.
-
Deal Watch May 2016
Paying a 55% premium at $99.25 per share, the acquisition brings crisaborole, a topical PDE4 inhibitor for mild to moderate atopic dermatitis (eczema) with estimated peak sales of $2bn. ... Corporate acquisition. Acquisition for $99.25 per share [55%
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
AIMM Therapeutics appoints former Novartis VP Jan de Vries as CEO
During his time at Novartis, de Vries led the discovery and early development of several drugs including Elidel (pimecrolimus) for eczema, Ilaris (canakunimab) for cryopyrin-associated periodic syndromes, Gilenya (fingolimod) for
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Living with psoriasis: a patient perspective
I would rather have an eczema flare-up than a psoriasis one. ... Whilst eczema hurts a lot more, it doesn’t look nearly as bad, and more often than not, I can fix it.”.
-
Havas Lynx Group lifts a silver Cannes Lion with landmark HIV campaign
experiential lift experience that not only stood out but also highlighted the injection as the first drug to treat severe eczema underneath the skin.
-
Atopic Dermatitis — Going Beyond the Pill
Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring ... Around 65% of patients in the US are
-
Bringing sufferers out of the shadows – Reducing the emotional impact of living with Atopic Dermatitis
Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring ... Around 65% of patients in the US are
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn
- Landscape review reveals £1.1bn of UK funding for rare diseases
- Cancer Research UK partners with French cancer institute
- New diagnosis pathway has been launched to mark European Myeloma Day
- Impacting Lives with Rare Disease Education
- Sandoz biosimilar receives EC approval to treat MS
No results were found
PMHub
Wave Healthcare Communications
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
